Clinical Trial Update: Phase 3 Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesophageal Junction Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating nimotuzumab plus irinotecan as second-line therapy for advanced or recurrent gastric and gastroesophageal junction cancer has been te…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• Irinotecan (Irinotecan)
• Nimotuzumab (nimotuzumab)

Snippet

Sponsor: Kuhnil Pharmaceutical Co., Ltd. | Conditions: Gastric Cancer, Gastroesophageal Junction Cancer | Phase 3 | Status: TERMINATED